Trials / Completed
CompletedNCT00674947
A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors
A Phase I Study of BIIB015, a Humanized, IgG1, DM4-Conjugated, Anti-Cripto, Monoclonal Antibody, for the Treatment of Subjects With Relapsed or Refractory Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1, open-labeled, safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIIB015 | IV infusion once every 3 weeks until disease progression or unacceptable toxicity |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2008-05-08
- Last updated
- 2013-09-16
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00674947. Inclusion in this directory is not an endorsement.